Pulmonary Embolism‐Attributable Mortality in Patients With Atherosclerotic Cardiovascular Disease in the United States from 2010 to 2023
7 affiliations
- 1University of Ferrara
- 2University of Padova
- 3University of Padua
- 4AULSS 6, Ospedali Riuniti Padova Sud
- 5West Vicenza Hospitals
- 6Brigham and Women's Hospital Harvard Medical School
- 7Harvard Medical School
Abstract
Background Patients with atherosclerotic cardiovascular disease (ASCVD) are at increased risk of pulmonary embolism (PE) and related mortality, yet contemporary US trends remain incompletely defined. We examined PE‐attributable mortality from 2010 to 2023 among patients with ASCVD, stratified by age, sex, race, ethnicity, urbanization, and region. Methods We used the Centers for Disease Control and Prevention's Wide‐Ranging Online Data for Epidemiologic Research data (2010–2023) to assess PE‐attributable mortality among patients with ASCVD aged ≥15 years using age‐adjusted mortality rates. Concurrent trends in age‐adjusted ASCVD prevalence and risk factors were evaluated using NHANES (National Health and Nutrition Examination Survey). Age‐adjusted mortality rates were analyzed with Joinpoint regression to estimate average annual percentage change (95% CI), and trends in NHANES were assessed using linear models. Results From 2010 to 2023, 152 386 US patients with ASCVD aged ≥15 years (80 015 male, 72 371 female) died from PE. PE‐attributable AAMR rose from 3.62 to 4.96 per 100 000 (annual percentage change +3.1%; P <0.001), with a modest increase from 2010 to 2018 (annual percentage change +0.7%, P =0.003) and a sharp rise from 2018 to 2023 (annual percentage change +12.8%, P <0.001). Age‐adjusted mortality rate was highest in non‐Hispanic/non‐Latinx Black American individuals, and American Indian/Alaska Native and Hispanic/Latinx populations had the steepest increases. Adults <65 years, rural areas, and the Western United States showed disproportionate rises, whereas the South had the highest absolute deaths. Such trends paralleled increasing ASCVD prevalence, which was driven by hypertension, obesity, diabetes, and chronic kidney disease. Conclusions PE‐attributable mortality among US patients with ASCVD rose from 2010 to 2023 particularly among young‐to‐middle‐aged adults, socioeconomically isolated ethnic and racial groups, and Western residents.
Related
- Mortality and Epidemiological Characteristics of Pulmonary Embolism in Spain (2022-2024)
- Development and Validation of a Predictive Model for 6-Month All-Cause Mortality in Pulmonary Embolism.
- Long-Term Outcomes of Mortality and CTEPH in Patients With Massive/Submassive Pulmonary Embolism Treated With Thrombolytics: Retro-Prospective Analysis
- Prognostic value of the C-reactive protein–albumin–lymphocyte index for predicting one-year mortality in acute pulmonary embolism
- Mortality trends and high-risk subgroups in hematologic malignancy-associated pulmonary embolism: a population-based analysis with complementary clinical data
BibTeX
@article{zuin2026pulmonary,
title = {{Pulmonary Embolism‐Attributable Mortality in Patients With Atherosclerotic Cardiovascular Disease in the United States from 2010 to 2023}},
author = {Marco Zuin and Claudio Bilato and Gianluca Rigatelli and Samuel Goldhaber and Gregory Piazza},
journal = {Journal of the American Heart Association},
year = {2026},
month = oct,
doi = {10.1161/jaha.126.049510},
url = {https://www.ahajournals.org/doi/10.1161/JAHA.126.049510},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Pulmonary Embolism‐Attributable Mortality in Patients With Atherosclerotic Cardiovascular Disease in the United States from 2010 to 2023
AU - Marco Zuin
AU - Claudio Bilato
AU - Gianluca Rigatelli
AU - Samuel Goldhaber
AU - Gregory Piazza
PY - 2026
DA - 2026/10/20
JO - Journal of the American Heart Association
DO - 10.1161/jaha.126.049510
UR - https://www.ahajournals.org/doi/10.1161/JAHA.126.049510
AB - Background Patients with atherosclerotic cardiovascular disease (ASCVD) are at increased risk of pulmonary embolism (PE) and related mortality, yet contemporary US trends remain incompletely defined. We examined PE‐attributable mortality from 2010 to 2023 among patients with ASCVD, stratified by age, sex, race, ethnicity, urbanization, and region. Methods We used the Centers for Disease Control and Prevention's Wide‐Ranging Online Data for Epidemiologic Research data (2010–2023) to assess PE‐attributable mortality among patients with ASCVD aged ≥15 years using age‐adjusted mortality rates. Concurrent trends in age‐adjusted ASCVD prevalence and risk factors were evaluated using NHANES (National Health and Nutrition Examination Survey). Age‐adjusted mortality rates were analyzed with Joinpoint regression to estimate average annual percentage change (95% CI), and trends in NHANES were assessed using linear models. Results From 2010 to 2023, 152 386 US patients with ASCVD aged ≥15 years (80 015 male, 72 371 female) died from PE. PE‐attributable AAMR rose from 3.62 to 4.96 per 100 000 (annual percentage change +3.1%; P <0.001), with a modest increase from 2010 to 2018 (annual percentage change +0.7%, P =0.003) and a sharp rise from 2018 to 2023 (annual percentage change +12.8%, P <0.001). Age‐adjusted mortality rate was highest in non‐Hispanic/non‐Latinx Black American individuals, and American Indian/Alaska Native and Hispanic/Latinx populations had the steepest increases. Adults <65 years, rural areas, and the Western United States showed disproportionate rises, whereas the South had the highest absolute deaths. Such trends paralleled increasing ASCVD prevalence, which was driven by hypertension, obesity, diabetes, and chronic kidney disease. Conclusions PE‐attributable mortality among US patients with ASCVD rose from 2010 to 2023 particularly among young‐to‐middle‐aged adults, socioeconomically isolated ethnic and racial groups, and Western residents.
SN - 2047-9980
ER -